[Funding alert] Warsaw-based Evidose Secures €455k in Funding

Read also - Amsterdam-based Biotech Startup Cradle Secures $24M in Series A Round Funding

With the objective of entering the European market early next year, Evidose is currently running pilots with its first Polish clients. The UK, Germany, France, and Benelux nations will be among the first to receive the service.

Anna Litwińska, co-founder and CEO of Evidose, said: “Understanding the true effectiveness of supplements is crucial for both consumer trust and industry credibility. While we often rely on generalized scientific research or EU regulatory approvals to gauge effects, the actual effectiveness of a supplement is influenced by multiple factors. These include not only the source of the substance and its chemical and physical properties but also individual differences such as genetics, lifestyle, and existing nutrient deficiencies. For instance, magnesium, which exists in at least 12 different forms, each with unique bioavailability, can be found in various formats like liquids, tablets, and capsules, offering different levels of absorption. We take all these factors into account to accurately assess each supplement’s effectiveness.”

Every facet of the testing procedure is managed by Evidose. This covers planning the research, enlisting volunteers, managing the testing, and interpreting the findings.

Read also - Stockholm-based Lassie Secures €23 Million in Series B Round Funding

Participating in this study provides insights into the effects of supplements on the body and advances industry transparency in the supplement sector. In addition to getting the supplement for testing, participants get access to a portal where they can record their continuing activities and respond to surveys about their health and well-being on an ongoing basis.

Kacper Zambrzycki, co-founder and COO of Evidose, commented: “The supplement industry is facing a big challenge, as there’s not enough clear and reliable information regarding the true effectiveness of these products. Consumers add supplements to their diets based on perceived benefits, only to discover through firsthand experience that many simply fall short of their promises. Brands that genuinely want to prove that their supplements work are in a tough spot. They have the option to test their products in clinical trials, just like pharmaceuticals, but this route is often prohibitively expensive and time-consuming. We plan to introduce a new kind of effectiveness study for supplements, one that is truly useful and trustworthy.”

Anna Litwińska is an outstanding information expert who skillfully blends scientific methods with practical business applications, all thanks to her experience in data science. She has had jobs with Zety, BOLD, OpenSignal, and the Royal Bank of Scotland in previous years.

Read also - Hexa Secures €20M for Launching 30 Startups Annually by 2030

Kacper Zambrzycki is an operational management specialist who has held prominent positions at AhoyConnect as Head of Operations, Inovo VC, and Tidio as Growth Manager.

Tomasz Swieboda, Managing Partner at Inovo VC, added: “Our decision to invest in Evidose stems from our confidence in the team’s capability to innovate a distinctive product. The combination of Anna and Kacper’s skills, coupled with their in-depth market insight, positions Evidose to potentially transform the use of supplements and wellness products by both consumers and manufacturers.”

About Evidose

Co-founded in 2023 by CEO Anna Litwińska and COO Kacper Zambrzycki, Evidose is leading the way in wellness industry innovation. The business is creating a special platform that will allow producers of wellness goods and dietary supplements to verify through science the actual benefits of their products on customer health.

This is an enormous leap over the current situation, in which the entire business depends on claims approved by the European Food Safety Authority (EFSA) or assumed, frequently unproven effects.